MarketPulse

preclinical stage

2 articles
The Motley FoolThe Motley Fool··Seena Hassouna

Specialist Biotech Fund's $25.8M Spyre Bet Signals Confidence in Preclinical Pipeline

VR Adviser increased Spyre Therapeutics stake by 1M shares to $120.74M. Stock surged 132% annually, but preclinical risks remain high for retail investors.
SYREbiotech investmentmonoclonal antibodies
The Motley FoolThe Motley Fool··Jonathan Ponciano

Commodore Capital Expands Spyre Therapeutics Position as Stock Climbs 63% YoY

Commodore Capital increases Spyre Therapeutics stake to $78.24M as stock surges 63% YoY. Biotech firm has $757M cash and expects Phase 2 data in 2026.
ALKSSYRERLAYXENEbiotechbalance sheet strength